# Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

> **NCT05352347** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shaperon** · enrollment: 1134 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** NuSepin® 0.2 mg/kg
- **DRUG:** NuSepin® 0.4 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05352347
- **Lead sponsor:** Shaperon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-12
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 1134 (ESTIMATED)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05352347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05352347, "Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05352347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*